Scalability of Sartobind® Rapid A Membrane for High Productivity Monoclonal Antibody Capture
Membranes · 27.09.2023 · 13 (10) · 815
DOI: 10.3390/membranes13100815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Membranes, online erschienen am 27.09.2023. Verfasst von Sabrina Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: CSL Innovation Pty Ltd., 655 Elizabeth Street, Melbourne, VIC 3000, Australia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSL Innovation Pty Ltd., Australia.
Abstract (Originalsprache)
Improved upstream titres in therapeutic monoclonal antibody (mAb) production have shifted capacity constraints to the downstream process. The consideration of membrane-based chromatographic devices as a debottlenecking option is gaining increasing attention with the recent introduction of high-capacity bind and elute membranes. We have evaluated the performance and scalability of the Sartobind® Rapid A affinity membrane (1 mL) for high-productivity mAb capture. For scalability assessment, a 75 mL prototype device was used to process 100 L of clarified cell culture harvest (CH) on a novel multi-use rapid cycling chromatography system (MU-RCC). MabSelect™ PrismA (4.7 mL) was used as a benchmark comparator for Protein A (ProtA) resin studies. Results show that in addition to a productivity gain of >10×, process and product quality attributes were either improved or comparable to the benchmark. Concentrations of eluate pools were 7.5× less than that of the benchmark, with the comparatively higher bulk volume likely to cause handling challenges at process scale. The MU-RCC system is capable of membrane operation at pilot scale with comparable product quality profile to the 1 mL device. The Sartobind® Rapid A membrane is a scalable alternative to conventional ProtA resin chromatography for the isolation and purification of mAbs from harvested cell culture media.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CSL Innovation Pty Ltd., 655 Elizabeth Street, Melbourne, VIC 3000, Australia.
- Sartorius Stedim Biotech GmbH, August-Spindler-Strasse 11, 37079 Goettingen, Germany.
- Sartorius Stedim Singapore Pte Ltd., 30 Pasir Panjang Rd., #06-31A/32, Singapore 117440, Singapore.
Förderung
- CSL Innovation Pty Ltd., Australia
Zitieren
APA
Yang, S., Braczkowski, R., Chen, S. H., Busse, R., Li, Y., Fabri, L., & Bekard, I. B. (2023). Scalability of Sartobind® Rapid A Membrane for High Productivity Monoclonal Antibody Capture. Membranes, 13(10), 815. https://doi.org/10.3390/membranes13100815
Vancouver
Yang S, Braczkowski R, Chen SH, Busse R, Li Y, Fabri L, et al. Scalability of Sartobind® Rapid A Membrane for High Productivity Monoclonal Antibody Capture. Membranes. 2023;13(10):815. doi:10.3390/membranes13100815
BibTeX
@article{Yang2023,
author = {Yang, Sabrina and Braczkowski, Ryszard and Chen, Shih-Hsun and Busse, Ricarda and Li, Yudhi and Fabri, Louis and Bekard, Innocent Berbelle},
title = {Scalability of Sartobind® Rapid A Membrane for High Productivity Monoclonal Antibody Capture},
journal = {Membranes},
year = {2023},
volume = {13},
number = {10},
pages = {815},
doi = {10.3390/membranes13100815}
}
EUVIMED